Hot Features
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck canc... Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -1.69491525424 | 0.59 | 0.59 | 0.58 | 902 | 0.58 | CS |
| 4 | -0.01 | -1.69491525424 | 0.59 | 0.6 | 0.54 | 2269 | 0.58127786 | CS |
| 12 | -0.03 | -4.91803278689 | 0.61 | 0.63 | 0.54 | 4118 | 0.5845075 | CS |
| 26 | 0.095 | 19.587628866 | 0.485 | 0.64 | 0.42 | 8867 | 0.5206836 | CS |
| 52 | 0.25 | 75.7575757576 | 0.33 | 0.64 | 0.27 | 12731 | 0.40993762 | CS |
| 156 | 0.26 | 81.25 | 0.32 | 0.64 | 0.17 | 13072 | 0.30574174 | CS |
| 260 | 0.335 | 136.734693878 | 0.245 | 0.64 | 0.15 | 15924 | 0.26735219 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.